Clinical trials: Lymphangiomyomatosis
Lymphatic Disorders
Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders
This is an open-label whole-body PET/CT study for investigating the value of 68Ga NEB PET imaging in the diagnosis and evaluation of lymphatic disorders including lymphedema, lymphangioma, lymphangioleiomyomatosis, plastic…
- Trial name
- NCT04273334
- Testing
- 68Ga-NEB
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Lymphangioleiomyomatosis
Letrozole for Lymphangioleiomyomatosis
The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the…
- Trial name
- TRAIL (NCT01353209)
- Testing
- Letrozole
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Cincinnati
Lymphangioleiomyomatosis (LAM), Extracellular Vesicles; Generation and Function
Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex
Lymphangioleiomyomatosis (LAM) is a rare lung disease, linked to Tuberous Sclerosis Complex (TSC) or occurring sporadically, and involves abnormal mTORC1 activation.
- Trial name
- NCT07304856
- Testing
- Pulmonary Function Test, Analysis of Extracellular Vesicles
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Milan
Pulmonary Lymphangioleiomyomatosis
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
This study is being done to determine if there is a potential benefit of saracatinib in LAM subjects. Based on the information of this trial, additional clinical development trials will be needed.
- Trial name
- SLAM-2 (NCT02737202)
- Testing
- saracatinib
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Tuberous Sclerosis, Lymphangioleiomyomatosis
Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
Tuberous Sclerosis Complex (TSC) is a multisystemic autosomal dominant disease that is characterized by the development of benign neoplasms in brain, kidney, lung, skin and heart.
- Conditions
- Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma
- Trial name
- NCT02325505
- Where
- 3 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- InCor Heart Institute
Lymphangioleiomyomatosis, Pulmonary Hypertension
Pulmonary Hypertension in Lymphangioleiomyomatosis
This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.
- Trial name
- LAM-PH (NCT00960895)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Lymphangioleiomyomatosis, LAM
Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM)
Data from patients with the orphan disease of lymphangioleiomyomatosis (LAM) which performed a pulmonary Rehabilitation program will be analyzed retrospectively.
- Conditions
- Lymphangioleiomyomatosis, LAM, Pulmonary Rehabilitation
- Trial name
- NCT04184193
- Testing
- Pulmonary Rehabilitation
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Sporadic Lymphangioleiomyomatosis, TSC-associated Lymphangioleiomyomatosis
The Genotype and Phenotype of Lymphangioleiomyomatosis
This study aims to differentiate between sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex-associated Lymphangioleiomyomatosis.
- Trial name
- NCT06405997
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Tuberous Sclerosis, Lymphangioleiomyomatosis
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.
- Trial name
- NCT00457808
- Testing
- Rapamycin, sirolimus
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lymphangioleiomyomatosis
A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
This trial is conducted locally. The aim of this trial is assess the efficacy and a favorable benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid
- Trial name
- LAM (NCT03062943)
- Testing
- Nintedanib
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Multimedica
Lymphangioleiomyomatosis
Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis (LAM) is a rare lung disease of women that is caused by genetic mutations. It results in the uncontrolled growth of an unusual type of smooth muscle cell in the lung.
- Trial name
- MILES (NCT00414648)
- Testing
- Sirolimus
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 89 people
- Sponsor
- University of Cincinnati
Lymphangioleiomyomatosis
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air.
- Trial name
- NCT01799538
- Testing
- albuterol inhaler, albuterol nebulizer, PFT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease)
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in respiratory failure patients and veno-arterial (V-A)…
- Conditions
- Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease), Bronchiectasis, Lymphangioleiomyomatosis
- Trial name
- NCT02859194
- Testing
- Veno-veno-arterial ECMO
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Yonsei University
Lymphangioleiomyomatosis
Discovery of Sirolimus Sensitive Biomarkers in Blood
Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive disease. It usually affects women in the prime of their lives. It typically results in lung destruction.
- Trial name
- NCT03304678
- Testing
- Sirolimus 2mg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Lymphangioleiomyomatosis
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare disease in which reduced exercise capacity is frequently present. The mechanisms applied are airflow obstruction, abnormal diffusion capacity and dynamic hyperinflation (DH).
- Trial name
- NCT02009241
- Testing
- Pulmonary Rehabilitation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Lymphangioleiomyomatosis
Effect of Loratadine in Lymphangioleiomyomatosis
INTRODUCTION: LAM is a rare and lethal disease characterized by progressive cystic lung destruction. Inhibition of mTOR with rapamycin is the current standard of care (SOC), which can slow-down disease.
- Trial name
- LORALAM (NCT05190627)
- Testing
- Loratadine
- Where
- 6 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Lymphangioleiomyomatosis
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis
- Trial name
- NCT01059318
- Testing
- Everolimus
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Lymphangioleiomyomatosis
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Specific Aim 1: To investigate whether, in Lymphangioleiomyomatosis (LAM) patients, the combination of sirolimus and hydroxychloroquine is safe and well tolerated Specific Aim 2: To investigate whether, in LAM patients, 6 months…
- Trial name
- SAIL (NCT01687179)
- Testing
- "Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Lymphangioleiomyomatosis, a Study on Cathepsin K
This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis.
- Trial name
- LAM-CAK (NCT05323370)
- Testing
- 24h urine, urine sample
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours